Gilead Sciences Inc.’s revenue rose 17% in the third quarter, helped by sales of its antiviral drug remdesivir that has become a standard treatment for hospitalized Covid-19 patients.
Yet sales of the company’s other drugs were hurt by pandemic-related shutdowns. And the company dialed back its forecast for overall revenue this year because of lower-than-expected hospitalization rates of Covid-19 patients.
Remdesivir,…
This post first appeared on wsj.com
